|Dr. Joseph K. Belanoff||Co-Founder, Pres, CEO & Director||1.52M||N/A||1957|
|Dr. Hazel Hunt Ph.D.||Chief Scientific Officer||674.87k||946k||N/A|
|Mr. Sean Maduck||Chief Commercial Officer||688.54k||N/A||1977|
|Mr. Gary Charles Robb||Chief Bus. Officer & Sec.||795.62k||N/A||1963|
|Mr. Atabak Mokari||Chief Financial Officer||N/A||N/A||1977|
|Mr. Joseph Douglas Lyon||Chief Accounting Officer||N/A||N/A||1978|
|Dr. Christopher Shayne James M.D.||Director of Investor Relations||N/A||N/A||N/A|
|Ms. Amy Flood||Chief HR & Communications Officer||N/A||N/A||N/A|
|Donald E. Laferle||Sr. VP||N/A||N/A||N/A|
|Dr. William Guyer Pharm.D.||Chief Devel. Officer||N/A||N/A||N/A|
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Corcept Therapeutics Incorporated’s ISS governance QualityScore as of 26 September 2021 is 8. The pillar scores are Audit: 10; Board: 5; Shareholder rights: 7; Compensation: 9.